ACE2 News and Research

RSS

Nucleocapsid protein preferentially binds to structured and longer RNA to deliver viral proteins in host circulation

Results from a new study could be crucial in studying the molecular and biochemical basis of SARS-CoV-2 infection at a more granular level and help in strategizing therapeutic solutions to treat and manage COVID-19 effectively.

5 Jan 2022

Can the COVID-19 delta variant evade vaccine-induced immunity?

Can the COVID-19 delta variant evade vaccine-induced immunity? We spoke to Professor Brian J. Willett from the University of Glasgow to find out.

5 Jan 2022

mRNA booster vaccine confers strong protection against SARS-CoV-2 Omicron in cancer patients

A new preprint research paper posted to the medRxiv* server reports the induction of high neutralizing activity in these patients against the Omicron VOC with a booster dose.

5 Jan 2022

Scientists provide a structural framework for Omicron immune evasion and ACE2 receptor recognition

An interesting preprint research paper describes structural changes resulting from the multiple mutations found in the recent Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is the causative agent behind the coronavirus disease 2019 (COVID-19) pandemic. In addition, the research describes the consequent effects of these changes on Omicron’s infectivity and immune evasion capabilities.

5 Jan 2022

Transplant recipients benefit from a COVID-19 vaccine booster

A new preprint research paper posted to the medRxiv* server describes the reduction in humoral immunity in SOTR following vaccination, as well as the improvement with an additional dose of the vaccine.

4 Jan 2022

Novel insight into the immune characteristics of bats

Many studies have indicated that bats are significant reservoirs of innumerable viruses, such as influenza, coronaviruses, and rabies. These studies have also reported that bats predominantly remain asymptomatic or develop mild diseases during viral infections caused by henipaviruses, Ebola virus, coronaviruses, etc.

4 Jan 2022

BNT162b2 provides low vaccine responders adequate anti-spike and neutralizing antibodies to prevent SARS-CoV-2

A new study, published on the medRxiv* preprint server, investigated the changes in SARS-CoV-2 antibody levels among HCWs after SARS-CoV-2 vaccination. The study also assessed whether low responders produced sufficient SARS-CoV-2 anti-spike and neutralizing antibodies.

4 Jan 2022

A closer look at the relationship between COVID-19 and Alzheimer’s disease

Researchers discuss the findings of previous studies on the role of SARS-CoV-2 infection in the progression of Alzheimer's Disease.

4 Jan 2022

Study finds pan-sarbecovirus nanobodies can enhance development of super-immunity

A new study found that applying pan-sarbecovirus nanobodies shows a strong affinity toward all sarbecovirus clades and neutralized SARS-CoV-2 receptor binding domains

4 Jan 2022

SARS-CoV-2 differs from other betacoronaviruses in a key IRE1α/XBP1 pathway

SARS-CoV-2 differs from other viruses in the beta coronavirus family in the activation of a key pathway associated with endoplasmic reticulum stress.

3 Jan 2022

The impact of natural selection on sequence diversity in SARS-CoV-2

Recent genomic analysis demonstrates that the SARS-CoV-2 genome is under two distinct selective forces.

3 Jan 2022

Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

Researchers investigate the capacity of vaccine-induced antibodies to generate Fc-effector activity against the SARS-CoV-2 Omicron variant.

3 Jan 2022

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Researchers combine SARS-CoV-2 spike vaccination with single-cell B-cell receptor sequencing technology to discover neutralizing antibody candidates.

3 Jan 2022

Study shows structural and functional aspects of antibody neutralization of SARS-CoV-2 Omicron variant

Researchers investigated the potency of trimeric human nephrocystin SH3, TriSb92, a domain-derived antibody, against a conserved region in the receptor-binding domain (RBD) of the spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern.

31 Dec 2021

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

New findings indicate that TriSb92 is a potent inhibitor of SARS-CoV-2 infection targeting a conserved site in the RBD of the spike, which is insensitive for immune escape mutations found in the relevant variants of concern, including Omicron

31 Dec 2021

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

A new study used in silico approaches for designing a next-generation CD40-targeting vaccine, CD40.

31 Dec 2021

How much do mutations reduce vaccine effectiveness in the Omicron variant?

In new research, scientists from Adaptive Biotechnologies have been investigating the impact of spike protein mutations on vaccine efficiency for the Omicron variant. The study is currently available on the medRxiv* preprint server while awaiting peer review.

30 Dec 2021

ACE2 News and Research

Nucleocapsid protein preferentially binds to structured and longer RNA to deliver viral proteins in host circulation

Can the COVID-19 delta variant evade vaccine-induced immunity?

mRNA booster vaccine confers strong protection against SARS-CoV-2 Omicron in cancer patients

Scientists provide a structural framework for Omicron immune evasion and ACE2 receptor recognition

Transplant recipients benefit from a COVID-19 vaccine booster

Novel insight into the immune characteristics of bats

BNT162b2 provides low vaccine responders adequate anti-spike and neutralizing antibodies to prevent SARS-CoV-2

A closer look at the relationship between COVID-19 and Alzheimer’s disease

Study finds pan-sarbecovirus nanobodies can enhance development of super-immunity

SARS-CoV-2 differs from other betacoronaviruses in a key IRE1α/XBP1 pathway

The impact of natural selection on sequence diversity in SARS-CoV-2

Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Study shows structural and functional aspects of antibody neutralization of SARS-CoV-2 Omicron variant

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

How much do mutations reduce vaccine effectiveness in the Omicron variant?

Clinical-grade soluble human ACE2 shown to inhibit SARS-CoV-2 Omicron variant

An integrated computational methodology for COVID drug prioritization

Omicron analysis shows no clear evidence for increased virulence or lethality

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News